Drug Profile
AT 132 - Livzon Mabpharm
Alternative Names: Anti-TNFα monoclonal antibody - Livzon; Anti-tumour necrosis factor alpha monoclonal antibody - Livzon; AT-132 - LivzonLatest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Livzon Group
- Developer Livzon Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Tumour necrosis factor alpha modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Sep 2022 No development reported - Phase-II for Autoimmune disorders in China (Parenteral) (Livzon Mabpharma website, September 2022)